1	Original Article
2	Are high urea values before intravenous immunoglobulin replacement a risk factor for
3	COVID-related mortality?
4	Running Title: Risk factors for COVID-related mortality?
5	
6	
7	Gökhan AYTEKİN ^{1,} *, Emel ATAYIK ¹
8	
	¹ Department of Immunology and Allergy, Konya City Hospital, Konya, Turkey
9	Department of minunology and Anergy, Konya City Hospital, Konya, Turkey
10	
11	*Correspondence: ayteking@gmail.com
12	
13	ORCIDs:
14	Gökhan AYTEKİN: https://orcid.org/0000-0002-9089-5914
15	Emel ATAYIK: https://orcid.org/ 0000-0002-7011-7752
16	
17	Corresponding Author:
18	Gokhan AYTEKIN, MD,
19	University of Health Sciences, Konya City Hospital,
20	Division of Allergy and Clinical Immunology,
21	42080, Konya Turkey
22	Phone: +90 505 533 73 55 Email: ayteking@gmail.com
23	
24	
25	
26	

2	7
2	1

28 Informed consent

- 29 The study protocol was approved by the Ethics committee of the Karatay University
- 30 (with the decision dated 09.02.2021, decision number: 2020/021). Informed consent
- 31 was obtained from study participants.
- 32 Manuscripts that have not been presented orally or as a poster.
- **Funding source:** No funding was secured for the study.
- 34 **Financial disclosure:** The authors have no financial relationship relevant to this article
- 35 to disclose.
- 36 **Conflict of interest:** The authors have no conflicts of interest to disclose.
- 37 Acknowledgement: None
- 38 **Disclaimers**: None
- 39 Abstract word count: 250
- 40 **Text word count:** 3097
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49

50 ORIGINAL ARTICLE

51 Title of the manuscript: Are high urea values before intravenous immunoglobulin52 replacement a risk factor for COVID-related mortality?

53 Abstract

Objective: Since the World Health Organization accepted The Coronavirus Disease 2019 (COVID-19) as a pandemic and there is still no effective treatment, it becomes crucial that the physicians interested in COVID-19 treatment share all the data they acquire, particularly in vulnerable patient groups, to reduce morbidity and mortality. Methods: The study included 81 adult (Female: 27, Male: 54) COVID-19 patients who were hospitalized for the treatment of COVID-19 between April 2020 and September

60 2020 and were followed-up, treated and consulted in the immunology clinic for61 intravenous immunoglobulin (IVIG) treatment.

Results: The univariate analysis found that the number of days of hospitalization in service, being intubated, number of IVIG treatment days, and the urea value before IVIG treatment were independent risk factors for mortality (p:0.043, p:0.001, p:0.074, p:0.004, respectively). As a result of multivariate analysis, being intubated and urea value before IVIG treatment were found to be independent risk factors for mortality (p:0.001 and p:0.009).

It was found that for 60 mg/dL level of urea value before IVIG treatment, the sensitivity
value for mortality in COVID-19 patients was 46.2%, and the specificity was 35.5%
(p:0.029)

Conclusion: The study found that urea values before IVIG treatment were a risk factor for mortality in patients who received IVIG treatment for COVID-19. This is important as it indicates that BUN values should be closely monitored in patients given IVIG

- 74 treatment for COVID-19. It also suggests that when resources are limited and risk
- rs stratification is required in COVID-19 patients, BUN values can be helpful.
- 76 Keywords: SARS-CoV-2, immunoglobulin, mortality, blood urea nitrogen, COVID-19

77 -

79 **1. Introduction**

80 The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (Sars-CoV-2), has affected the whole world in economic, 81 82 social, spiritual, and many other areas, particularly in the field of health, since 83 December 2019, when it was first described (1, 2). As the disease is highly contagious, 84 the virus spread worldwide in a short time and caused one of the most catastrophic pandemics in human history (3). Although there are some vaccines to reduce virus 85 86 transmission and develop protection against it, it is obvious that vaccinating all the 87 people in the world will not be possible in such short term. Although it has been more 88 than one year since the WHO (World Health Organization) accepted COVID-19 as a pandemic, there is still no effective treatment. Until now, many treatment options, 89 90 particularly antimalarial drugs and antivirals, systemic corticosteroids, tocilizumab, anakinra, conventional plasma therapy, and intravenous immunoglobulin (IVIG) 91 92 therapy, have been tried in the form of monotherapy or combinations for treating 93 COVID-19, there is still no consensus on its treatment (4-7).

94

95 For this reason, it becomes crucial that the physicians interested in COVID-19 treatment 96 share all the data they acquire, particularly in vulnerable patient groups, to reduce 97 morbidity and mortality. Regarding COVID-19 treatment management, many countries have created their treatment protocols, and many associations have published guidelines 98 99 for its treatment. COVID-19 treatment in Turkey has been primarily applied in line with 100 the TC Ministry of Health protocols. In general, the patients positive for SARS-CoV-2 101 Polymerase Chain Reaction (PCR) (+) were put on hydroxychloroquine and favipiravir 102 treatment at appropriate doses. Patients who did not benefit from these treatments

and/or had underlying risk factors were hospitalized. In addition to respiratory support
treatments, patients were treated with conventional plasma, systemic steroid therapy,
immunomodulatory therapies such as tocilizumab and anakinra, and IVIG treatment,
whichever appropriate, as line therapies (8). IVIG was administered as per the clinical
immunologists' opinions and in the proper dose and time intervals.

108 Considering that pulmonary lesions in COVID-19 are caused by viral infiltrates and inflammatory response, IVIG treatment provides inflammatory cytokine balance, 109 inhibits auto-reactive T cells, reduces antibody production from CD19⁺ B cells, and 110 reduces macrophage activity. The IVIG treatment is thought to provide a regression in 111 112 pulmonary lesions, reducing the need for mechanical ventilation, length of hospital stay, and mortality rates in these patients (9, 10). Therefore, this study aimed to 113 retrospectively examine the data of patients who reported to the immunology clinic for 114 IVIG treatment in a tertiary referral hospital and who were hospitalized, followed up, 115 and treated for COVID-19. The study also investigated the effects of the patients' 116 117 clinical, laboratory, and treatment characteristics and risk factors for mortality in 118 patients with COVID-19 treating with IVIG treatment.

119 **2.** Methods

120 Study design and study population

The study included 81 adult (Female [F]: 27, 33.3%; Male [M]: 54, 66.7%) COVID-19 patients who were hospitalized for the treatment of COVID-19 in a tertiary referral hospital between April 2020 and September 2020 and were followed-up, treated and consulted in the immunology clinic for IVIG treatment. A review of medical records (including information on age, sex, disease duration) was undertaken. Venous blood samples for biochemical analyses were drawn after at least ten hours of fasting, early in

the morning. All biochemical analyses were conducted in the Central BiochemistryLaboratory of the Konya Education and Research Hospital.

Complete blood counts were performed using Sysmex XN-10 (Sysmex Corporation, Kobe, Japan) analyzers with the fluorescent flow cytometry method. Serum creatinine levels were measured using the Jaffe method. Quantitative determination of serum IgG, IgM, IgA, and IgE was done through particle-enhanced immunonephelometry using the Siemens BN II/BN ProSpec system (Erlangen, Germany). The follow-up period of all patients started with their hospitalization. For the patients

who died, the number of days between the date of hospitalization and death was 135 136 accepted as the follow-up period. The duration of follow-up was calculated by confirming whether the discharged patients were alive or not through the TC Death 137 138 Reporting System 2 weeks after discharge. For patients who died within two weeks of discharge, the follow-up period was accepted as the number of days between the date of 139 140 hospitalization and death. For patients who lived more than two weeks after discharge, 141 the follow-up period was calculated by adding 14 days to the number of days they 142 stayed in the hospital.

The time until hospitalization, resulting from the emergence of SARS-CoV-2-related symptoms such as fever, cough, and body pain, was considered the duration of illness. The duration of the follow-up in the service was specified as the day of hospitalization and the follow-up period in the intensive care unit as the duration of intensive care hospitalization. All patients in the study received IVIG treatment. Some patients were followed only in the service and received IVIG treatment in the service. Some patients received IVIG treatment in the intensive care unit. Patients who received IVIG

treatment in the service and those who received IVIG treatment in the first 24/48 h after
their admission to intensive care were specified as the IVIG treatment ICU first 24/48 h.

The systemic inflammatory index (SII) was calculated by the formula platelet x neutrophil/lymphocyte. The SARS-CoV-2 diagnosis was established with the detection of the SARS-CoV-2 genome via the PCR method from the nasopharyngeal sample (nasal swab) in patients with symptoms suggestive of SARS-CoV-2 infection such as fever, cough, shortness of breath, joint and body pain, and/or viral infiltration on lung imaging (PA chest radiography or lung tomography).

The permission for the study was obtained from the Republic of Turkey, Ministry of Health Scientific Research Platform. In addition, an ethics committee approval was obtained from Karatay University Ethics Committee (with the decision dated 09.02.2021, decision number: 2020/021). Written informed consent was obtained from each patient. The study was conducted as per the principles of the Declaration of Helsinki.

164 Statistical Analyses

165 Statistical analyses were performed using the SPSS version 22.0 software package 166 (IBM Corp., Armonk, NY, USA). Normally distributed parameters were presented as 167 mean ±standard deviation, and data that were not normally distributed were expressed as median (interquartile range: minimum-maximum). Descriptive data were presented 168 169 as frequencies and percentages and compared using the Chi-square test. Comparisons 170 between baseline characteristics were performed by independent Student t, Mann-Whitney rank-sum, Fisher's exact or Chi-square tests where appropriate. Independent 171 172 predictors for mortality were determined using binomial logistic regression analysis, 173 Cox regression analysis, and Kaplan-Meier test. ROC curves are used to choose the

most appropriate cut-off for urea level. A *p*-value of <0.05 was considered statistically
significant.

176

177 **3. Results**

178 A total of 81 patients, 27 of whom were women (33.3%), were included in the study. The average age of the patients was 71 (26–94) years. During the follow-up, the 179 mortality rate was 64.2%. The rate of intubated patients was 45.7%. The average 180 181 follow-up period was 19 (1-38) days. The duration of hospitalization was 17 (1-38)days, and the duration of hospitalization in intensive care was 10 (0-30) days. All 182 183 patients received hydroxychloroquine and favipiravir treatment during their follow-up. In addition, IVIG treatment was given to all patients. While 35 patients (43.2%) 184 185 received tocilizumab treatment, 15 patients (18.5%) received conventional plasma and 33 patients (40.7%) received pulse steroid treatment. 61.7% of the patients in the first 186 24 h of their admission to intensive care, and 64.2% of the patients in the first 48 h of 187 188 their admission to intensive care received IVIG treatment. The demographic, laboratory, 189 and clinical characteristics of the patients have been summarized in Table 1.

190 There was no statistically significant difference between the patients who died during their follow-up and the patients who survived in terms of age, gender, tocilizumab 191 treatment, conventional plasma treatment, and the number of days of hospitalization in 192 the service. We observed significant differences in terms of intubated patient ratio, pulse 193 steroid therapy, hospitalization white blood cell count, hospitalization platelet count, 194 195 lymphocyte percentage before IVIG treatment, neutrophil count before IVIG treatment, hospitalization C-reactive protein (CRP) values, CRP levels before IVIG treatment, urea 196 197 values before IVIG treatment, hospitalization lactate dehydrogenase (LDH) levels,

hospitalization systemic inflammatory index (SII) levels, SII levels before IVIG
treatment, and NLR (Neutrophil Lymphocyte Ratio) levels before IVIG treatment. The
comparison of demographic, laboratory, and clinical characteristics of the patients who
died and survived has been summarized in Table 1.

The univariate analysis found that the number of days of hospitalization in service, being intubated, number of IVIG treatment days, and the urea value before IVIG treatment were independent risk factors for mortality (p:0.043, p:0.001, p:0.074, p:0.004, respectively) (Table 2). As a result of multivariate analysis, being intubated and urea value before IVIG treatment were found to be independent risk factors for mortality (p:0.001 and p:0.009, respectively) (Table 3).

It was found that for 60 mg/dL level of urea value before IVIG treatment, the sensitivity value for mortality in COVID-19 patients receiving IVIG treatment was 46.2%, and the specificity was 35.5% (p:0.029) (Table 4) (Figure 1).

211

212 **4. Discussion**

213 The SARS-CoV-2 virus has caused one of the most severe pandemics in human history 214 and has put a lot of pressure, particularly on healthcare systems, since March 2020, when it was declared as a pandemic by WHO. The SARS-CoV-2 virus has caused the 215 216 deaths of approximately 3 million people in nearly one year since its outbreak (2, 11). 217 At present, there is no globally accepted treatment scheme for treating patients 218 hospitalized for COVID-19. Therefore, it is crucial to determine the prognostic factors 219 in vulnerable patient groups and to develop treatment modalities specific to patient 220 groups according to these factors to reduce mortality and morbidity. In line with this 221 opinion, this study found that being intubated and urea values before IVIG treatment are

independent risk factors for COVID-19-related mortality in patients hospitalized forCOVID-19 and given IVIG treatment.

224 It has been reported that 7% of COVID-19 patients develop acute renal failure (12, 13). 225 In addition, renal failure has been reported to increase COVID-19-related hospital 226 deaths in mortality studies (14-19). Cheng et al. (15) showed an increase in blood urea 227 nitrogen increased mortality 3.97 times in COVID-19 patients. Another study reported 228 that hospitalization blood urea nitrogen (BUN) and D-dimer levels were associated with 229 mortality, and BUN values of \geq 4.6 mmol/L included a high risk for hospital deaths (14). In another study, 6.29% of COVID-19 patients showed an increase in BUN, and 230 231 increased basal BUN and creatinine values were reported to cause high mortality (17). Ng et al. (18) reported that being intubated and BUN values are risks for hospital 232 233 mortality in patients with end-stage renal disease and COVID-19. Although the increase 234 in BUN after SARS-CoV-2 is frequent, the reason for this increase is not clear. Renal 235 epithelial cells contain angiotensin-converting enzyme 2 (ACE2) receptors that are 100 236 times more intense than respiratory epithelial cells; SARS-CoV-2 is internalized to renal 237 cells and may cause renal function loss with cytopathic effect (15, 20). It has been 238 suggested that this may increase the absorption of BUN from the renal tubules by 239 activating the renin-angiotensin-aldosterone system (20). Although IVIG treatment is 240 often used as one of the last treatment options in patients who do not respond to other treatments, IVIG treatment itself may be associated with renal damage (13). 241

On the other hand, the increase in BUN levels in COVID-19 patients may be an indicator of kidney dysfunction and an increased inflammatory state. The renal load caused by increased catabolism, hypovolemia-induced renal hypoperfusion, sepsis, drugs used in the treatment of COVID-19 such as steroid therapy, and rhabdomyolysis

246 may also cause an increase in BUN. Although creatinine, another indicator of renal 247 damage, was not found to be a predictor of mortality in this study, the fact that BUN is 248 predictive of mortality suggests that BUN increases due to inflammatory conditions 249 rather than a renal-induced reason and that increased inflammatory processes play a role 250 in making BUN a risk factor for mortality. Another situation supporting this hypothesis 251 is that inflammatory markers of the patients who died before IVIG treatment were 252 prominently higher and statistically significant than the alive patients. As the most 253 common cause of mortality in COVID-19 is a respiratory failure caused by cytokine storm, the majority of patients (81.5%) in the present study had to be followed up in the 254 255 intensive care unit due to deterioration in their clinical condition. IVIG treatment is one of the last options in COVID-19 patients who are unresponsive to other therapies and 256 257 whose cytokine storms are not controlled. It was thought that these patients face an intense inflammatory process, which causes an increase in BUN. 258

The retrospective design, relatively small study population, lack of evaluation of other renal markers such as proteinuria and hematuria, and lack of knowledge of what happened in the post-follow-up period form the main limitations of this study.

262 **5.** Conclusion

In conclusion, the study found that urea values before IVIG treatment were a risk factor for mortality in patients who received IVIG treatment for COVID-19. This is important as it indicates that BUN values should be closely monitored in patients given IVIG treatment for COVID-19. It also suggests that when resources are limited and risk stratification is required in COVID-19 patients, BUN values can be helpful.

268

```
270
```

271

272 **References**

- Liu X, Liu C, Liu G, Luo W, Xia N. COVID-19: Progress in diagnostics,
 therapy and vaccination. Theranostics 2020; 10(17): 7821-35. 2020/07/21. doi:
- 275 10.7150/thno.47987.
- 276 2. Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a
- 277 global health crisis. Physiol Genomics 2020; 52(11): 549-57. 2020/09/30. doi:
- 278 10.1152/physiolgenomics.00089.2020.
- Ferrer R. [COVID-19 Pandemic: the greatest challenge in the history of critical
 care]. Med Intensiva (Engl Ed) 2020; 44(6): 323-4. 2020/05/08. doi:
- 281 10.1016/j.medin.2020.04.002.
- 4. Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: Discovery,
- diagnostics and drug development. Journal of hepatology 2021; 74(1): 168-84.
- 284 2020/10/11. doi: 10.1016/j.jhep.2020.09.031.
- 5. Echeverria-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio
 Cusco M, Ferrandez O, Horcajada JP, et al. Azithromycin in the treatment of COVID19: a review. Expert review of anti-infective therapy 2021; 19(2): 147-63. 2020/08/28.
- 288 doi: 10.1080/14787210.2020.1813024.
- 289 6. Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: An overview.
 290 European journal of pharmacology 2020; 889: 173644. 2020/10/15. doi:
- 291 10.1016/j.ejphar.2020.173644.
- 292 7. Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2:
- 293 Structure, Biology, and Structure-Based Therapeutics Development. Frontiers in
- cellular and infection microbiology 2020; 10: 587269. 2020/12/17. doi:
- 295 10.3389/fcimb.2020.587269.
- 8. Bakanlığı TCS, Müdürlüğü HSG. COVID-19 rehberi antisitokin-anti inflamatua
 rtedaviler koagulopati yonetimi. 2020, 7 November.
- Mazeraud A, Goncalves B, Aegerter P, Mancusi L, Rieu C, Bozza F, et al. Effect
 of early treatment with polyvalent immunoglobulin on acute respiratory distress
- syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a
- 301 randomized controlled trial. Trials 2021; 22(1): 170. 2021/03/03. doi: 10.1186/s13063-
- 302 021-05118-7.
- 303 10. Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. Effect of regular
- intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with
 COVID-19. J Infect 2020; 81(2): 318-56. 2020/04/14. doi: 10.1016/j.jinf.2020.03.044.
- 306 11. Worldometer. COVID-19 CORONAVIRUS PANDEMIC. 2021, March 28.
- 12. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute
- kidney injury in patients hospitalized with COVID-19. Kidney Int 2020; 98(1): 209-18.
 2020/05/18. doi: 10.1016/j.kint.2020.05.006.
- 310 13. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin:
- adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29(3): 173-84.
- 312 2006/01/05. doi: 10.1385/CRIAI:29:3:173.

313 14. Cheng A, Hu L, Wang Y, Huang L, Zhao L, Zhang C, et al. Diagnostic 314 performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients. International journal of antimicrobial 315 316 agents 2020; 56(3): 106110. 2020/07/28. doi: 10.1016/j.ijantimicag.2020.106110. 317 15. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020; 97(5): 318 319 829-38. 2020/04/06. doi: 10.1016/j.kint.2020.03.005. Liu Q, Wang Y, Zhao X, Wang L, Liu F, Wang T, et al. Diagnostic Performance 320 16. 321 of a Blood Urea Nitrogen to Creatinine Ratio-based Nomogram for Predicting In-322 hospital Mortality in COVID-19 Patients. Risk management and healthcare policy 2021; 14: 117-28. 2021/01/21. doi: 10.2147/rmhp.S278365. 323 324 17. Liu YM, Xie J, Chen MM, Zhang X, Cheng X, Li H, et al. Kidney Function Indicators Predict Adverse Outcomes of COVID-19. Med (New York, NY) 2021; 2(1): 325 38-48.e2. 2020/10/13. doi: 10.1016/j.medj.2020.09.001. 326 327 18. Ng JH, Hirsch JS, Wanchoo R, Sachdeva M, Sakhiya V, Hong S, et al. 328 Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. 329 Kidney Int 2020; 98(6): 1530-9. 2020/08/19. doi: 10.1016/j.kint.2020.07.030. 330 19. Shao M, Li X, Liu F, Tian T, Luo J, Yang Y. Acute kidney injury is associated with severe infection and fatality in patients with COVID-19: A systematic review and 331 332 meta-analysis of 40 studies and 24,527 patients. Pharmacological research 2020; 161: 105107. 2020/08/03. doi: 10.1016/j.phrs.2020.105107. 333 Nogueira SAR, Oliveira SCS, Carvalho AFM, Neves JMC, Silva L, Silva Junior 334 20. GBD, et al. Renal changes and acute kidney injury in covid-19: a systematic review. 335 Rev Assoc Med Bras (1992) 2020; 66Suppl 2(Suppl 2): 112-7. 2020/09/24. doi: 336 10.1590/1806-9282.66.S2.112. 337 338 339 340 341 342 343 344 345 346 347

- 348
- 349

350

351 Table 1: Baseline demographic, clinical, and laboratory parameters of the study

352 population

Variable	Total (n: 81)	Dead (n:52)	Alive (n: 29)	р
Age	72 (41-94)	73.0 (41-94)	61 (46-78)	0.391
Gender, F, n (%)	27 (33.3)	17 (32.7)	10 (34.5)	0.870
Follow up time, day	19 (1-60)	20 (1-38)	16 (3-60)	0.745
Duration of illness, day	7 (3-10)	7 (3-10)	7 (3-8)	0.846
Day of stay in hospital	16 (1-44)	17 (1-38)	16 (3-44)	0.557
Day of stay in inpatient service	7.90 ±5.98	7.15 ±6.03	9.24 ±5.75	0.133
Day of stay in intensive care	10 (0-31)	9.5 (0-31)	13 (2-21)	0.509
Intensive care, n (%)	66 (81.5)	48 (92.3)	18 (62.1)	0.001
Intubation, n (%)	37 (45.7)	34 (65.2)	3 (10.3)	0.001
Comorbidity	60 (74.1)	40 (76.9)	20 (69.0)	0.433
Treatment properties				
Convalescent plasma, n (%)	15 (18.5)	9 (17.3)	6 (20.7)	0.707
Pulse steroid therapy, n	33 (40.7)	28 (53.8)	5 (17.2)	0.001
(%)				
Tocilizumab treatment, n (%)	35 (43.2)	19 (36.5)	16 (55.2)	0.105
IVIG treatment, at least	68 (84)	42 (80.8)	26 (89.7)	0.296

three days, n (%)				
IVIG treatment, in first	50 (61.7)	30 (57.7)	20 (69.0)	0.317
24 h, n, %				
IVIG treatment, in first	52 (64.2)	32 (61.5)	20 (69.0)	0.504
48 h, n, %				
Duration of IVIG	3 (1-5)	3 (1-5)	3 (2-5)	0.069
treatment, day				
IVIG dose, gr/day	40 (25-50)	40 (25-50)	50 (30-50)	0.832
Hematological paramete	rs			
WBC count, on	7,960 (1,176-	8,185 (1,176-	7,349.31	0.020
hospitalization	27,350)	27,350)	(2,630-20,110)	
WBC count, before IVIG	9,570 (430-	11,955 (430-	8,190 (1,220-	0.008
treatment	27,290)	27,290)	25,920)	
Neutrophil count, on	7,156.94	7,716.58	6,153	0.136
hospitalization,	±4,508.17	±4,459.34	±4,496.95	
Neutrophil percentage,	84.50 (26.10-	85.50 (26.10-	78.10 (50.20-	0.100
on	96.60)	96.60)	94.20)	
hospitalization				
Lymphocyte count, on	770 (300-	690 (300-	780 (600-	0.512
hospitalization	1,777)	1,770)	1,510)	
Lymphocyte percentage,	11.30 (2.20-	9.30 (2.20-0)	12 (3-33.10)	0.081
on hospitalization	33.10)			
Lymphocyte count,	520 (130-	460 (130-	730 (140-	0.294
before IVIG treatment	1,670)	1,490)	1,670)	

Lymphocyte percentage,	4.30 (0.80-	3.35 (0.80-	5.60 (2.60-	0.001
before IVIG treatment	46.50)	46.50)	35.70)	
Platelet count, $x10^3$, on	192 (71-442)	204 (71-372)	191 (75-422)	0.030
hospitalization				
Platelet count, $x10^3$,	244.19 ±112.82	240.92 ±122.01	250.04 ±95.88	0.730
before IVIG treatment				
Eosinophil count, on	0 (0-130)	0 (0-130)	0 (0-80)	0.689
hospitalization				
Eosinophil percentage,	0 (0-1.20)	0 (0-0.90)	0 (0-1.20)	0.994
on				
hospitalization				
Eosinophil count, before	0 (0-180)	0 (0-180)	0 (0-120)	0.077
IVIG treatment				
RDW, on hospitalization	12.40 ±2.58	12.32 ±2.61	12.55 ±2.56	0.706
RDW, before IVIG	11.80 (8.40-	12.05 (9.40-	10.80 (8.40-	0.394
treatment	20.40)	20.40)	17.70)	
Biochemical Parameters				
Fasting blood glucose,	140 (75-480)	154 (84-361)	122 (75-480)	0.034
mg/dL, on				
hospitalization				
Fasting blood glucose,	165 (77- 344)	180 (88-344)	123 (77-263)	0.195
before IVIG treatment				
Urea, on	42 (15-256)	42.50 (15-256)	41 (17-180)	0.863
hospitalization				

Urea, before IVIG	59 (17-230)	60.50 (33-230)	43 (17-79.10)	0.029
treatment				
Creatine, on	1.03 (0.58-	1.04 (0.58-	1.02 (0.6-2.20)	0.629
hospitalization	6.87)	6.87)		
Creatine, before IVIG	0.8 (0.5-2.60)	0.9 (0.52-2.60)	0.80 (0.50-	0.544
treatment			1.22)	
LDH, on	457 (188-	516 (190-	384 (188-	0.012
hospitalization	4,367)	4,367)	1,015)	
LDH, before IVIG	570.81 ±213.58	597.10 ±201.48	524.59 ±229.67	0.145
treatment				
D-dimer, on	0.90 (0.20-	0.80 (0.20-	0.90 (0.30-	0.775
hospitalization	5.70)	5.70)	2.10)	
D-dimer, before IVIG	4.59 ±7.59	4.93 ±7.98	3.87 ±6.93	0.549
treatment				
Fibrinogen, on	707.47 ±228.52	720.08 ±247.29	685.39 ±193.60	0.525
hospitalization				
Fibrinogen, before IVIG	635.22 ±279.67	636.81 ±278.53	632.81 ±286.64	0.950
treatment				
Ferritin, on	475.10 (43-	550 (43-4,568)	114 (90.2-	0.389
hospitalization	4568)		1,305)	
Ferritin, before IVIG	655 (83-3,345)	699 (83-3,345)	623 (114-	0.613
treatment			1,659)	
IgG, on hospitalization	8.36 ±4.04	9.64 ±2.70	7.08 ±4.87	0.188
IgM, on hospitalization	0.60 ±0.41	0.58 ±0.49	0.62 ±0.33	0.859

IgA, on hospitalization	2.52 (0	.37-	2.56	(0.37-	2.42	(0.37-	0.198
	7.62)		7.62)		7.62)		
Inflammatory Markers							
CRP, on hospitalization	91.2 (3-415))	124 (3-4	15)	53.70	(8.52-	0.015
					317)		
CRP, before IVIG	47.0 (3.10-2	297)	82.05	(3.10-	20.80	(3.10-	0.012
treatment			297)		197)		
SII, on hospitalization	1834.	97	1953.0		1064	(352.87-	0.016
	(254.19-		(254.19-		12,962	2.43)	
	12,962.43)		11,059.8	4)			
SII, before IVIG	4,166.94		5,086.86		3,753.	21	0.013
treatment	(657.69-		(657.69-		(1,354	.69-	
	22,356.46)		22,356.4	6)	13,441	.37)	
NLR, on hospitalization	9.19 (1	.86-	9.28	(1.93-	7.24	(1.86-	0.075
	42.21)		42.21)		30.72)	1	
NLR, before IVIG	23.21 (2	.33-	26.08	(2.33-	16.15	(5.80-	0.001
treatment	126.31)		126.31)		27.66)	I	

F: Female, IVIG: Intravenous immunoglobulin, WBC: White blood cell, RDW: Red
cell distribution wide, MPV: Mean platelet volume, ALT: Alanine aminotransferase,
AST: Aspartate Aminotransferase, LDH: Lactate dehydrogenase, Ig: Immunoglobulin,
CRP: C-reactive protein, SII: Systemic inflammatory index, NLR: Neutrophil
lymphocyte ratio

359 **Table 2:** Univariate Cox regression analyses demonstrating the relationship between

360 baseline characteristics and Sars-CoV-2

Variable	Univariate Analysis			
	HR (95% CI)	P value		
Day of stay in inpatient service	0.951 (0.906 – 0.998)	0.043		
Intubation	16.370 (4.353-61.565)	0.001		
Intensive care	0.923 (0.316-0.270)	0.884		
Pulse steroid therapy	0.910 (0.525 – 1.580)	0.738		
Tocilizumab treatment	1.436 (0.794 – 2.552)	0.236		
Duration of IVIG treatment, day	1.419 (0.966 – 2.083)	0.074		
IgG, on hospitalization	1.234 (0.964 – 1.581)	0.096		
WBC, before IVIG treatment	1.000 (1.000 – 1.000)	0.418		
Neutrophil count, on hospitalization	1.000 (1.000 – 1.000)	0.946		
Platelet count, on hospitalization	1.001 (0.998 – 1.004)	0.405		
Eosinophil count, IVIG öncesi	0.994 (0.983 – 1.006)	0.307		
FBG, on hospitalization	1.002 (0.998 – 1.005)	0.299		
FBG, before IVIG treatment	1.002 (0.999 – 1.006)	0.192		
Urea, before IVIG treatment	1.011 (1.003 – 1.018)	0.004		
LDH, on hospitalization	1.000 (0.999 – 1.000)	0.722		
LDH, before IVIG treatment	1.000 (0.999 – 1.001)	0.695		
IgA, on hospitalization	1.025 (0.740 – 1.421)	0.880		
CRP, on hospitalization	1.002 (0.999 – 1.005)	0.111		
CRP, before IVIG treatment	1.001 (0.998 – 1.005)	0.364		

SII, on hospitalization	1.000 (1.000 – 1.000)	0.746
SII, before IVIG treatment	1.000 (1.000 – 1.000)	0.314
NLR, on hospitalization	1.002 (0.979 – 1.025)	0.884
NLR, before IVIG treatment	1.004 (0.994 – 1.014)	0.414

Sars-CoV-2: Severe Acute Respiratory Syndrome causing Coronavirus, F: Female,
IVIG: Intravenous immunoglobulin, WBC: White blood cell, RDW: Red cell
distribution wide, MPV: Mean platelet volume, ALT: Alanine aminotransferase, AST:
Aspartate Aminotransferase, FBG: Fasting blood glucose, LDH: Lactate
dehydrogenase, Ig: Immunoglobulin, CRP: C-reactive protein, SII: Systemic
inflammatory index, NLR: Neutrophil lymphocyte ratio

367

368

369

370 **Table 3**: Multivariate Cox regression analyses demonstrating the relationship between

371 baseline characteristics and Sars-CoV-2

Variables	Multivariate Analysis		
	HR (95% CI)	P value	
Intubation	0.389 (0.218 – 0.693)	0.001	
Day of stay in inpatient service	0.968 (0.915 – 1.024)	0.256	
Duration of IVIG treatment, day	0.833 (0.652 – 1.065)	0.145	
Urea, before IVIG treatment	1.009 (1.002 – 1.017)	0.009	

³⁷² Sars-CoV-2: Severe Acute Respiratory Syndrome causing Coronavirus, IVIG:


373 Intravenous immunoglobulin


Table 4: Sensitivity and specificity of urea level before IVIG treatment

	Risk factor	AUC (95%)	Cut-off	р	Sensitivity	Specificity
	Urea, before IVIG	0.647	60	0.029	46.2	35.5
	treatment	(0.518 - 0.776)				
376	AUC: Area under the	curve, IVIG: Intrav	enous imm	unoglobul	in	
377						

378

Figure 1: Sensitivity and specificity of urea level before IVIG treatment





380